Maidenhead, UK, 28 June 2018 – A big rise in the number of doctors willing to consent to their transfers of value being made public is reported in AbbVie submission to the Association of the British Pharmaceutical Industry annual industry-wide Transfer of Value disclosure. 78 per cent (Nearly 4 in 5) of doctors who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2017 opted-in for their individual data to be made public in the scheme. AbbVie is encouraged that this marks increased confidence in AbbVie transparency from the medical profession. The input of medical opinion to our work is vital to ensure we are focusing on what patients need and the pharmaceutical research industry provides a vital role in keeping medical education up to date with science.
Overall the total sum that AbbVie invests in working with and supporting UK healthcare organisations and doctors remained broadly flat in 2017 compared to the year before with a rise of three per cent to £11.5m. Of this figure nearly two thirds (57 per cent) is on the administration of clinical trials – demonstrating the enduring importance of the UK as a centre of excellence in the development of new medicines.
The full set of AbbVie data is available from the ABPI disclosure UK web portal at: http://www.disclosureuk.org.uk/
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.